BEIJING – Compared to the US, China has relatively few innovative therapies, which leaves much room for smaller companies to improve on current treatments and thrive in the process.
In 2015, the US FDA set a record for innovative new drug approvals, while China still lags far behind. But...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?